Latest & greatest articles for carvedilol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on carvedilol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on carvedilol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for carvedilol

1. Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer (Abstract)

Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer Trastuzumab is highly effective for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer but is associated with a decline in left ventricular ejection fraction.The purpose of this study was to determine whether angiotensin-converting enzyme inhibitors or beta-blockers reduce the rate of trastuzumab-induced cardiotoxicity (left ventricular ejection fraction (...) decrease >10%, or >5% if below 50%) and limit treatment interruptions.In this double-blind, multicenter, placebo-controlled trial, cardiotoxicity and treatment interruptions in patients with HER2-positive breast cancer treated with trastuzumab for 12 months were evaluated over a 2-year period. Patients were stratified by anthracycline use and then randomized to receive lisinopril, carvedilol, or placebo.The study included 468 women, age 51 ± 10.7 years. For the entire cohort, cardiotoxicity

2019 EvidenceUpdates

2. Carvedilol

Carvedilol Top results for carvedilol - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for carvedilol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

3. Endothelial Phenotype Evoked by Low Dose Carvedilol in Pulmonary Hypertension. Full Text available with Trip Pro

Endothelial Phenotype Evoked by Low Dose Carvedilol in Pulmonary Hypertension. Background: The therapeutic benefits of β-blockers are well established in left heart failure. The Pulmonary Arterial Hypertension Treatment with Carvedilol for Heart Failure [PAHTCH] study showed safety and possible benefit of carvedilol in pulmonary arterial hypertension (PAH) associated right heart failure over 6 months. This study aims at evaluating the short-term cardiovascular effects and early mechanistic (...) biomarkers of carvedilol therapy. Methods: Thirty patients with pulmonary hypertension (PH) received low dose carvedilol (3.125 mg twice daily) for 1 week prior to randomization to placebo, low-dose, or dose-escalating carvedilol therapy. Echocardiography was performed at baseline and 1 week. Exercise capacity was assessed by 6 min walk distance (6MWD). The L-arginine/nitric oxide pathway and other biological markers of endothelial function were measured. Results: All participants tolerated 1 week

2018 Frontiers in cardiovascular medicine Controlled trial quality: uncertain

4. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis (Abstract)

A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis. More recent data suggest that carvedilol may be more effective for reducing the hepatic venous pressure gradient (HVPG) than propranolol. The primary aim of this study was to evaluate the hemodynamic response to carvedilol compared (...) with propranolol.A total of 110 patients with a baseline HVPG value >12 mm Hg were allocated randomly to receive either carvedilol or propranolol. The HVPG measurement was repeated after 6 weeks of daily medication. The primary end point was a ≥20% fall in HVPG compared with baseline or <12 mm Hg.The difference in the proportion of responders in the carvedilol (49.1%) vs. propranolol (30.9%) groups did not reach statistical significance in the intention-to-treat analysis (P=0.08). However, among patients

2016 EvidenceUpdates Controlled trial quality: uncertain

5. Carvedilol

Carvedilol USE OF CARVEDILOL IN PREGNANCY 0344 892 0909 USE OF CARVEDILOL IN PREGNANCY (Date of issue: February 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Carvedilol is a non-cardioselective beta-adrenoceptor blocking drug licensed for the treatment of hypertension, angina pectoris (...) and symptomatic chronic heart failure (CHF). There are no studies of rates of specific pregnancy outcomes following gestational exposure to carvedilol. An evidence-based assessment of the potential risks of congenital malformation, spontaneous abortion, stillbirth, intrauterine growth restriction (IUGR), preterm delivery and adverse neurodevelopmental effects following in utero exposure is therefore not possible and women should be made aware of this lack of data. Studies of beta-blockers as a class have

2014 UK Teratology Information Service

6. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial

BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2011 PedsCCM Evidence-Based Journal Club

7. Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure (Abstract)

Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure Atrial fibrillation (AF) occurs frequently soon after coronary artery bypass grafting (CABG) and often results in increased mortality and morbidity, particularly in patients with heart failure. New-onset AF is also a common event in the early period after discharge from a cardiac surgery clinic. Current guidelines (...) recommend β blockers as first-line medication for the prevention of AF after CABG. In this prospective study, we investigated the effectiveness of the highly selective β1 receptor antagonist bisoprolol compared to the less selective β blocker carvedilol in preventing postdischarge AF after CABG in patients with decreased left ventricular function. Three hundred twenty patients (231 men, 89 women, mean age 66 ± 10 years) with ejection fraction <40% who underwent CABG and were then referred

2011 EvidenceUpdates Controlled trial quality: uncertain

8. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients (Abstract)

Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients Vasoconstricting beta-blocker use is associated with a reduction in HDL cholesterol, higher triglyceride, total cholesterol and LDL cholesterol levels, whereas carvedilol, a vasodilating beta-blocker, has not been associated with these effects.To compare in a randomized, double-blind study, the effects of the beta 1-blocker metoprolol tartrate with the combined alpha 1, beta-blocker carvedilol (...) on serum lipid concentrations.A prospective randomized, double-blind, parallel-group trial compared the effects of carvedilol and metoprolol on total cholesterol, triglycerides, calculated LDL, HDL and non-HDL cholesterol levels at baseline and after 5 months of therapy as a secondary objective in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensive (GEMINI) study. In this study, 1235 participants with type 2 diabetes and hypertension who were receiving renin

2009 EvidenceUpdates Controlled trial quality: predicted high

9. Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure

Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure Article Text Therapeutics Carvedilol was more effective than metoprolol for preventing

2008 Evidence-Based Medicine

10. Effect of exercise training and carvedilol treatment on cardiac function and structure in mice with sympathetic hyperactivity-induced heart failure. (Abstract)

Effect of exercise training and carvedilol treatment on cardiac function and structure in mice with sympathetic hyperactivity-induced heart failure. The present investigation was undertaken to study the effect of beta-blockers and exercise training on cardiac structure and function, respectively, as well as overall functional capacity in a genetic model of sympathetic hyperactivity-induced heart failure in mice (alpha(2A)/alpha(2C)ArKO). alpha(2A)/alpha(2C)ArKO and their wild-type controls were (...) studied for 2 months, from 3 to 5 months of age. Mice were randomly assigned to control (N = 45), carvedilol-treated (N = 29) or exercise-trained (N = 33) groups. Eight weeks of carvedilol treatment (38 mg/kg per day by gavage) or exercise training (swimming sessions of 60 min, 5 days/week) were performed. Exercise capacity was estimated using a graded treadmill protocol and HR was measured by tail cuff. Fractional shortening was evaluated by echocardiography. Cardiac structure and gastrocnemius

2008 Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas

11. Impact of carvedilol on the serum lipid profile Full Text available with Trip Pro

Impact of carvedilol on the serum lipid profile Impact of carvedilol on the serum lipid profile Impact of carvedilol on the serum lipid profile Sharp RP, Sirajuddin R, Sharief IM CRD summary This review concluded that β 1 -selective antagonists worsened the lipid profile compared to carvedilol and that it was unclear whether carvedilol independently made an improvement or had a neutral effect. The review had several methodological flaws and the authors' conclusions are not likely to be reliable (...) . Authors' objectives To assess the impact of carvedilol on the serum lipid profile. Searching MEDLINE and International Pharmaceutical Abstracts were searched for published studies between 1966 and December 2007. Search terms were reported. Study selection Studies that evaluated the impact of carvedilol on the lipid profile were selected for inclusion. Studies of off-label use of carvedilol were excluded. Patients in included studies had hypertension or diabetes mellitus. Comparator treatments included

2008 DARE.

12. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. Full Text available with Trip Pro

Carvedilol for children and adolescents with heart failure: a randomized controlled trial. Although beta-blockers improve symptoms and survival in adults with heart failure, little is known about these medications in children and adolescents.To prospectively evaluate the effects of carvedilol in children and adolescents with symptomatic systemic ventricular systolic dysfunction.A multicenter, randomized, double-blind, placebo-controlled study of 161 children and adolescents with symptomatic (...) systolic heart failure from 26 US centers. In addition to treatment with conventional heart failure medications, patients were assigned to receive placebo or carvedilol. Enrollment began in June 2000 and the last dose was given in May 2005 (each patient received medication for 8 months).Patients were randomized in a 1:1:1 ratio to twice-daily dosing with placebo, low-dose carvedilol (0.2 mg/kg per dose if weight <62.5 kg or 12.5 mg per dose if weight > or =62.5 kg), or high-dose carvedilol (0.4 mg/kg

2007 JAMA Controlled trial quality: predicted high

13. Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP Full Text available with Trip Pro

Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP Article Text

2006 Evidence-Based Medicine

14. Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure Full Text available with Trip Pro

Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure Article Text Therapeutics Carvedilol was more effective than metoprolol tartrate

2005 Evidence-Based Medicine

15. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Full Text available with Trip Pro

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers.To compare the effects of beta-blockers with different pharmacological profiles on glycemic and metabolic control in participants with DM (...) and hypertension receiving renin-angiotensin system (RAS) blockade, in the context of cardiovascular risk factors.A randomized, double-blind, parallel-group trial (The Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives [GEMINI]) conducted between June 1, 2001, and April 6, 2004, at 205 US sites that compared the effects of carvedilol and metoprolol tartrate on glycemic control. The 1235 participants were aged 36 to 85 years with hypertension (>130/80 mm Hg) and type 2 DM

2004 JAMA Controlled trial quality: predicted high

16. Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan

Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Inomata T, Izumi T, Kobayashi M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two treatments for the care of chronic heart failure (CHF) were under evaluation. The treatments compared were the addition of carvedilol to conventional therapies and conventional therapies alone. The conventional therapies included the concomitant use of angiotensin-converting enzyme (ACE) inhibitors, diuretics and digitalis. The treatment regimes were low-dose (5 mg/day

2004 NHS Economic Evaluation Database.

17. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Full Text available with Trip Pro

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Beta blockers reduce mortality in patients who have chronic heart failure, systolic dysfunction, and are on background treatment with diuretics and angiotensin-converting enzyme inhibitors. We aimed to compare the effects of carvedilol and metoprolol on clinical outcome.In a multicentre, double-blind (...) , and randomised parallel group trial, we assigned 1511 patients with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1518 to metoprolol (metoprolol tartrate, target dose 50 mg twice daily). Patients were required to have chronic heart failure (NYHA II-IV), previous admission for a cardiovascular reason, an ejection fraction of less than 0.35, and to have been treated optimally with diuretics and angiotensin-converting enzyme inhibitors unless not tolerated. The primary

2003 Lancet Controlled trial quality: predicted high

18. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. (Abstract)

Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. The improvement in left-ventricular ejection fraction (LVEF) in response to beta blockers is heterogeneous in patients with heart failure due to ischaemic heart disease, possibly indicating variations in the myocardial substrate underlying left-ventricular dysfunction. We investigated whether improvement in LVEF was associated (...) with the volume of hibernating myocardium (viable myocardium with contractile failure).We did a double-blind, randomised trial to compare placebo and carvedilol for 6 months in individuals with stable, chronic heart failure due to ischaemic left-ventricular systolic dysfunction. We enrolled 489 patients, of whom 387 were randomised. Patients were designated hibernators or non-hibernators according to the volume of hibernating myocardium. The primary endpoint was change in LVEF, measured by radionuclide

2003 Lancet Controlled trial quality: predicted high

19. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. (Abstract)

Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. Beta-blockers remain underused despite their established utility for improving outcome in heart failure. Concerns that initiation of treatment produces few immediate benefits and may have important risks may be deterring widespread use.To evaluate the early effects of the beta-blocker carvedilol in patients with severe heart failure.Randomized, double-blind, placebo-controlled (...) trial conducted from October 28, 1997, to March 20, 2000, at 334 hospital centers in 21 countries among 2289 patients with symptoms of heart failure at rest or with minimal exertion who were clinically euvolemic and had a left ventricular ejection fraction of less than 25%.Patients were randomly assigned to receive carvedilol, with start dosage of at 3.125 mg twice daily with uptitration to a target dosage of 25 mg twice daily (n = 1156), or placebo (n = 1133), in addition to their usual medications

2003 JAMA Controlled trial quality: predicted high

20. Cost-effectiveness for the management of chronic heart failure: cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan

Cost-effectiveness for the management of chronic heart failure: cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Cost-effectiveness for the management of chronic heart failure: cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Cost-effectiveness for the management of chronic heart failure: cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Inomata T Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of beta-blockers (carvedilol in particular) for chronic heart failure (CHF). The doses in the present study were not specified, but doses of 5 and 20 mg/day were mentioned from the literature. Type

2003 NHS Economic Evaluation Database.